Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
Matteo Righi(Autolus (United Kingdom)), Martin Pulé(Autolus (United Kingdom))
Cited by 10
Related Papers
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
|Molecular Therapy|2023|31
Large-scale manufacturing of base-edited chimeric antigen receptor T cells
|Molecular Therapy — Methods & Clinical Development|2023|15
Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy
|Molecular Therapy — Nucleic Acids|2023|11
Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike
|BIO-PROTOCOL|2021|4
Novel Fas-TNFR chimeras that prevents Fas ligand-mediated kill and signals synergistically to enhance CAR T-cell efficacy
|bioRxiv (Cold Spring Harbor Laboratory)|2023|0